<DOC>
	<DOCNO>NCT01098474</DOCNO>
	<brief_summary>This purpose study assess safety immunogenicity GSK Biologicals ' candidate tuberculosis vaccine ( 692342 ) administer concomitantly Expanded Programme Immunisation vaccine regimen healthy infant age include 2 7 month , live tuberculosis endemic region .</brief_summary>
	<brief_title>Safety Immunogenicity Study Candidate Tuberculosis Vaccine Healthy Infants</brief_title>
	<detailed_description />
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female subject investigator believe parent ( ) / Legally Acceptable Representative ( LAR ( ) ) comply requirement protocol . Written oral , sign thumbprinted witness informed consent obtain subject 's parent ( ) /LAR ( ) . Subjects received birth dose Bacille Calmette Guerrin . Healthy subject establish medical history clinical examination enter study . For 'Outside Expanded Programme Immunisation ' cohort : Must document evidence he/she complete primary Expanded Programme Immunisation regimen least 1 month prior plan vaccination investigational vaccination regimen . Aged 5 7 month time first study vaccination . For 'Within EPI ' cohort : Must receive birth dose Bacille Calmette Guerrin , oral polio vaccine Hepatitis B vaccine NO Expanded Programme Immunisation vaccine . Aged 2 4 month time first study vaccination diphtheria , tetanus , whole cell pertussis/ Haemophilus influenzae type b vaccine + pneumococcal conjugate vaccine + oral polio vaccine . Child care Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal abnormality , determine physical examination and/or laboratory screen test . Laboratory screen test range , investigator 's opinion affect ability child take part study . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . A family history congenital hereditary immunodeficiency . Major congenital defect . History neurological disorder seizure . Any condition illness medication , opinion investigator might interfere evaluation safety immunogenicity study vaccine . Any finding investigator feel would increase risk adverse outcome participation trial . Acute disease and/or fever time enrolment . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . For 'Within Expanded Programme Immunisation ' Cohort : Previous vaccination diphtheria , tetanus , pertussis , Haemophilus influenzae type b pneumococcal conjugate vaccine . History previous administration experimental Mycobacterium tuberculosis vaccine . Administration immunoglobulins , blood transfusion and/or blood product since birth first dose study vaccine plan administration study period . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned participation concurrently participate another clinical study time study period , subject expose investigational noninvestigational product . Any chronic drug therapy continue study period , exception vitamin and/or dietary supplement History allergic reaction anaphylaxis vaccine . History reaction hypersensitivity likely exacerbate component study vaccine . Severe malnutrition screening define weightforage Zscore &lt; 3 standard deviation . Children enrol maternal , obstetrical neonatal event occur might , judgment investigator , result increase neonatal/infant morbidity .</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>7 Months</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Tuberculosis vaccine</keyword>
</DOC>